Biostatistics Events

Biostatistics Departmental Calendar

Event
Mon 6/1/2020 11:00AM - 1:00PM
Biostatistics Dissertation Defense
Jun Zhang-Interpretable Analysis of Multivariate Functional Data-ONLINE Biostatistics Dissertation Defense
Jun Zhang-Interpretable Analysis of Multivariate Functional Data-ONLINE
Mon 6/1/2020 11:00AM - 1:00PM
** Online/Virtual Event **

Jun Zhang of the Department of Biostatistics defends her dissertation on "Interpretable Analysis of Multivariate Functional Data". 


** Online/Virtual Event **
Sat 8/1/2020 to Thu 8/6/2020
Biostatistics Conference
Joint Statistical Meetings - - JSM 2020, Philadelphia, PA Biostatistics Conference
Joint Statistical Meetings - - JSM 2020, Philadelphia, PA
Sat 8/1/2020 to Thu 8/6/2020


The Joint Statistical Meetings, known simply as "JSM", is the largest gathering of statisticians held annually in North American. Faculty and student presenters from the  Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations. Our students often receive top awards and participate in the affiliated career marketplace at the event.


Sun 3/14/2021 to Wed 3/17/2021
Biostatistics Conference
ENAR 2021 Spring Meeting of the International Biometric Society -- Baltimore Biostatistics Conference
ENAR 2021 Spring Meeting of the International Biometric Society -- Baltimore
Sun 3/14/2021 to Wed 3/17/2021


Meetings of the Eastern North American Region of the International Biometric Society (a.k.a. "ENAR meetings") are held in late March or early April each year and reflect the broad interests of the Society, including both quantitative techniques and application areas. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations.


Sat 8/7/2021 to Thu 8/12/2021
Biostatistics Conference
Joint Statistical Meetings - - JSM 2021, Seattle, WA Biostatistics Conference
Joint Statistical Meetings - - JSM 2021, Seattle, WA
Sat 8/7/2021 to Thu 8/12/2021


The Joint Statistical Meetings, known simply as "JSM", is the largest gathering of statisticians held annually in North American. Faculty and student presenters from the  Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations. Our students often receive top awards and participate in the affiliated career marketplace at the event.


Sun 3/27/2022 to Wed 3/30/2022
Biostatistics Conference
ENAR 2022 Spring Meeting of the International Biometric Society -- Houston Biostatistics Conference
ENAR 2022 Spring Meeting of the International Biometric Society -- Houston
Sun 3/27/2022 to Wed 3/30/2022


Meetings of the Eastern North American Region of the International Biometric Society (a.k.a. "ENAR meetings") are held in late March or early April each year and reflect the broad interests of the Society, including both quantitative techniques and application areas. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations.


Sat 8/6/2022 to Thu 8/11/2022
Biostatistics Conference
Joint Statistical Meetings - - JSM 2022, Washington, DC Biostatistics Conference
Joint Statistical Meetings - - JSM 2022, Washington, DC
Sat 8/6/2022 to Thu 8/11/2022


The Joint Statistical Meetings, known simply as "JSM", is the largest gathering of statisticians held annually in North American. Faculty and student presenters from the  Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations. Our students often receive top awards and participate in the affiliated career marketplace at the event.


Recent Events

Biostatistics Dissertation Defense

Judah Abberbock: Usage of Surrogate Endpoints in the Design and Analysis of Clinical Trials

Monday 7/17 2:00PM - 4:00PM
7139 Public Health, Peterson Seminar Room

Judah Abberbock of the Department of Biostatistics defends his dissertation on "Usage of Surrogate Endpoints in the Design and Analysis of Clinical Trials"

Graduate faculty of the University and all other interested parties are invited to attend


ABSTRACT:

There has been a shift in the conduct of early-stage breast cancer trials in recent years from long adjuvant trials with overall or disease-free survival as the efficacy endpoint to shorter neoadjuvant trials with pathological complete response (pCR), a binary marker, at time of surgery as the endpoint. The Food and Drug Administration (FDA) currently embraces this transition and deems evidence in pCR improvement sufficient for drug approval on condition that long-term data are collected to eventually show efficacy in survival. Incorporating data on pCR in the design and analysis of such a trial is therefore of public health interest. Here, we propose one method to assess the power and sample size of such a trial with using observed neoadjuvant data and another method to estimate certain causal treatment effects on survival conditional on pCR. In the first part, we propose an exponential mixture model for survival time with parameters for the response rates and an estimated benefit in survival from achieving response. Under a fixed sample size, we obtain the empirical power through simulations from the proposed mixture model. We also propose a more efficient method than the empirical approach by applying an estimated average hazard ratio to the Schoenfeld formula. The performance of our methods is assessed via simulation studies. Data from two neoadjuvant cancer clinical trials are used to illustrate these methods. Second, we propose a method under the principal stratification framework to estimate the causal effect of treatment on a binary outcome, conditional on a post-treatment binary response marker in randomized controlled clinical trials. Specifically, we estimate the treatment effect among those who would achieve response if given the treatment. We are able to identify this causal effect under two assumptions. First, we model the counterfactual probability of achieving response under treatment given baseline clinical markers and the outcome. Second, we assume a monotonicity condition: a patient who responds under control would respond under treatment as well. We compared the performance of proposed method with other standard approaches in simulation studies. Data from a neoadjuvant breast cancer clinical trial are used to demonstrate the proposed method.

Last Updated On Monday, October 23, 2017 by Valenti, Renee Nerozzi
Created On Tuesday, May 30, 2017

AprMay 2020Jun
SunMonTueWedThuFriSat
262728293012
3456789
10111213141516
17181920212223
24252627282930
31123456

Submit events and news

Click to enter calendar events or share news and announcements.